Clinical trial · Observational
The Perceived Mismatch Between Dose Recommendations of PKI's and the Clinical Practice
NCT06402812CI-TRIAL-00076834completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A qualitative research study will be conducted using semi-structured interviews. The target population includes regulators involved in the registration of PKIs and healthcare professionals who use PKIs in clinical practice. Participants will be recruited until a rich understanding of the subject is reached.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Interview | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Regulators
- description
- Regulators
- interventionNames
- Other: Interview
- label
- Proefssionals
- description
- Professionals
- interventionNames
- Other: Interview
Primary outcomes (1)
- measure
- Interview
- timeFrame
- 3 months
- description
- Spoken words of participants will be gathered via interviews which have been conducted following an pre-set up interview guide.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
Show eligibility criteria text
Inclusion Criteria: \- Regulators involved in the regulation of oncolytic products. Healthcare professionals who prescribe PKI's as a treatment for cancer in clinical practice (e.g. oncologists). Exclusion Criteria: * No exclusion criteria will be maintained.
References
Publications (0)
Data not yet available
No reference posted for this study.